Shockwave Medical (SWAV) has disclosed a new risk, in the Corporate Activity and Growth category.
Shockwave Medical faces significant business risk if the proposed Merger with Johnson & Johnson fails to materialize. Conditions outside of Shockwave Medical’s control, such as regulatory approvals and antitrust clearances, are critical to the Merger’s completion. Failure could lead to a substantial drop in share price, a hefty $448.0 million termination fee, and potential reputational damage. The company’s relationships and financial health may suffer, with no guarantee of recovery to pre-announcement stability.
Overall, Wall Street has a Hold consensus rating on SWAV stock based on 2 Buys, 1 Sell and 8 Holds.
To learn more about Shockwave Medical’s risk factors, click here.
